- Home
- ONCY vs SCLX Comparison
ONCY vs SCLX Comparison
Compare ONCY & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- SCLX
- Stock Information
- Founded
- ONCY 1998
- SCLX 2011
- Country
- ONCY Canada
- SCLX United States
- Employees
- ONCY N/A
- SCLX N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- SCLX Health Care
- Exchange
- ONCY Nasdaq
- SCLX Nasdaq
- Market Cap
- ONCY 56.2M
- SCLX 72.5M
- IPO Year
- ONCY 1999
- SCLX N/A
- Fundamental
- Price
- ONCY $0.69
- SCLX $0.39
- Analyst Decision
- ONCY Strong Buy
- SCLX Strong Buy
- Analyst Count
- ONCY 2
- SCLX 4
- Target Price
- ONCY $4.00
- SCLX $14.00
- AVG Volume (30 Days)
- ONCY 2.6M
- SCLX 184.3K
- Earning Date
- ONCY 03-06-2025
- SCLX 01-17-2025
- Dividend Yield
- ONCY N/A
- SCLX N/A
- EPS Growth
- ONCY N/A
- SCLX N/A
- EPS
- ONCY N/A
- SCLX N/A
- Revenue
- ONCY N/A
- SCLX $55,152,000.00
- Revenue This Year
- ONCY N/A
- SCLX $32.77
- Revenue Next Year
- ONCY N/A
- SCLX $50.71
- P/E Ratio
- ONCY N/A
- SCLX N/A
- Revenue Growth
- ONCY N/A
- SCLX 22.02
- 52 Week Low
- ONCY $0.67
- SCLX $0.37
- 52 Week High
- ONCY $1.53
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- ONCY 34.93
- SCLX 41.41
- Support Level
- ONCY $0.67
- SCLX $0.37
- Resistance Level
- ONCY $0.72
- SCLX $0.48
- Average True Range (ATR)
- ONCY 0.05
- SCLX 0.04
- MACD
- ONCY -0.01
- SCLX 0.00
- Stochastic Oscillator
- ONCY 9.48
- SCLX 34.32
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.